Our results showed that BCL6 inhibition exerted little effect on ROS production in KRAS-mutant lung cancer cells (Supplemental Figure 9), thus excluding the role of ROS in BCL6-mediated tumor-promoting action in the context of KRAS mutational activation. Here, KRAS is linked to lung carcinoma.